In a significant development for the biotech sector, Roth Capital has recently adjusted its third-quarter 2025 earnings per share (EPS) estimates for GeoVax Labs Inc. This revision highlights a notable shift in analyst expectations, providing crucial insights into the company’s financial trajectory.

Analyst J. Aschoff of Roth Capital now projects GeoVax Labs to report a narrower loss of ($0.24) per share for Q3 2025, an improvement from their previous forecast of ($0.27). Furthermore, Roth Capital’s comprehensive financial forecast extends to Q4 2025 with an EPS of ($0.23), full-year 2025 at ($1.16) EPS, 2026 at ($0.97) EPS, and an optimistic $0.23 EPS for FY2027, signaling a potential turnaround.

This updated Roth Capital forecast is not isolated, as several other research firms have also weighed in on GeoVax Labs’ prospects. D. Boral Capital and HC Wainwright have both reiterated “buy” ratings with price targets of $9.00 and $8.00 respectively, while Alliance Global Partners adjusted their target to $8.50 with a “buy” rating. Conversely, one firm lowered its stance to a “sell” rating, contributing to a “Moderate Buy” consensus rating and an average target price of $8.88 for the company.

From a market performance perspective, GeoVax Labs recently opened at $0.72 per share, navigating a 52-week range spanning from a low of $0.43 to a high of $11.18. The company’s current market capitalization stands at $11.54 million, alongside a price-to-earnings ratio of -0.36 and a beta of 3.27, reflecting its volatility within the market.

The recent Q3 earnings report offered mixed signals. GeoVax Labs announced an EPS of ($0.35), outperforming the consensus estimate of ($0.41) by a notable $0.06. Revenue for the quarter reached $0.85 million, significantly surpassing analyst projections of $0.37 million, indicating stronger-than-expected top-line performance.

Despite the revenue beat, the company’s financial health indicators reveal challenges. GeoVax Labs recorded a negative net margin of 403.88% and a negative return on equity of 408.80%. These figures underscore the significant operational costs and profitability hurdles the biotech firm is currently addressing.

Institutional investors have shown varying degrees of engagement with GeoVax Labs stock. Armistice Capital LLC initiated a new stake worth $703,000, while Geode Capital Management LLC increased its position by 59.0%. Other significant moves include new positions established by Citadel Advisors LLC, Jane Street Group LLC, and Northern Trust Corp, collectively accounting for 6.09% institutional ownership in the company.

The diverse analyst opinions, coupled with recent financial results and strategic institutional investments, paint a complex picture for GeoVax Labs. Investors are closely monitoring how these earnings estimates and shifting market dynamics will influence the company’s future valuation and its standing within the competitive biotech sector. This biotech stock analysis provides a comprehensive market outlook for potential stakeholders seeking to understand the implications of the latest Roth Capital forecast on GeoVax Labs and broader investor insights.